Cover Image
市場調查報告書

溴結構域蛋白3:開發中產品分析

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 516024
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
溴結構域蛋白3:開發中產品分析 Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 50 Pages
簡介

本報告提供以溴結構域蛋白3為標的之治療藥開發相關資訊,提供開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

溴結構域蛋白3;概要

溴結構域蛋白3;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • Merck & Co Inc
  • Nuevolution AB
  • Resverlogix Corp
  • Trillium Therapeutics Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC0838TDB

Summary

According to the recently published report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2017'; Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets.

The report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2017' outlays comprehensive information on the Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 4 and 3 respectively. Report covers products from therapy areas Oncology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Follicular Lymphoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lymphoma, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)
  • The report reviews Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Overview
    • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd
    • Forma Therapeutics Inc
    • Incyte Corp
    • Merck & Co Inc
    • Nuevolution AB
    • Resverlogix Corp
    • Trillium Therapeutics Inc
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Drug Profiles
    • birabresib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPI-0610 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FT-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-54329 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NUE-7770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6146 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVX-2135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTI-281 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEN-3694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Dormant Products
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Discontinued Products
  • Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
      • Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
      • Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016
      • Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
      • Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
      • Mar 18, 2015: New Data Investigating Merck's MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
      • Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
      • Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
      • Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
      • Jan 31, 2013: OncoEthix Doses First Patient In Phase I Trial Of OTX015 For Treatment Of Hematologic Malignancies
      • Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
      • Nov 21, 2012: Oncoethix Recevies FDA Clearance For Phase I Trial Of OTX015 In Patients With Advanced Hematologic Malignancies
      • Nov 09, 2012: Oncoethix Reports Preclinical Activity Of OTX015 At 24th EORTX-NCI-AACR Symposium
      • Aug 16, 2012: Researchers Develop Potential Male Contraceptive Pill
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pipeline by Forma Therapeutics Inc, H1 2017
  • Pipeline by Incyte Corp, H1 2017
  • Pipeline by Merck & Co Inc, H1 2017
  • Pipeline by Nuevolution AB, H1 2017
  • Pipeline by Resverlogix Corp, H1 2017
  • Pipeline by Trillium Therapeutics Inc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top